Literature DB >> 9129591

Selection of neutralizing antibody escape mutants with type A influenza virus HA-specific polyclonal antisera: possible significance for antigenic drift.

S M Cleveland1, H P Taylor, N J Dimmock.   

Abstract

Ten antisera were produced in rabbits by two or three intravenous injections of inactivated whole influenza type A virions. All contained haemagglutination-inhibition (HI) antibody directed predominantly to an epitope in antigenic site B and, in addition, various amounts of antibodies to an epitope in site A and in site D. The ability of untreated antisera to select neutralization escape mutants was investigated by incubating virus possessing the homologous haemagglutinin with antiserum adjusted to contain anti-B epitope HI titres of 100, 1000 and 10,000 HIU/ml. Virus-antiserum mixtures were inoculated into embryonated hen's eggs, and progeny virus examined without further selection. Forty percent of the antisera at a titre of 1000 HIU/ml selected neutralizing antibody escape mutants as defined by their lack of reactivity to Mab HC10 (site B), and unchanged reactivity to other Mabs to site A and site D epitopes. All escape mutant-selecting antisera had a ratio of anti-site B (HC10)-epitope antibody:other antibodies of > or = 2.0:1. The antiserum with the highest ratio (7.4:1) selected escape mutants in all eggs tested in four different experiments. No antiserum used at a titre of 10,000 HIU/ml allowed multiplication of any virus. All antisera used at a titre of 100 HIU/ml permitted virus growth, but this was wild-type (wt) virus. We conclude that a predominant epitope-specific antibody response, a titre of > or = 1000 HIU/ml, and a low absolute titre of other antibodies (< or = 500 HIU/ml) are three requirements for the selection of escape mutants. None of the antisera in this study could have selected escape mutants without an appropriate dilution factor, so the occurrence of an escape mutant-selecting antiserum in nature is likely to be a rare event.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9129591      PMCID: PMC2808776          DOI: 10.1017/s0950268896007303

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  7 in total

1.  Truncation and sequence shuffling of segment 6 generate replication-competent neuraminidase-negative influenza H5N1 viruses.

Authors:  Donata Kalthoff; Susanne Röhrs; Dirk Höper; Bernd Hoffmann; Jessica Bogs; Jürgen Stech; Martin Beer
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  Heterogeneity of influenza B virus strains in one epidemic season differentiated by monoclonal antibodies and nucleotide sequences.

Authors:  N Nakagawa; R Kubota; A Maeda; T Nakagawa; Y Okuno
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

3.  Immune-induced evolutionary selection focused on a single reading frame in overlapping hepatitis B virus proteins.

Authors:  Yaakov Maman; Antoine Blancher; Jennifer Benichou; Adi Yablonka; Sol Efroni; Yoram Louzoun
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

4.  Highly pathogenic avian influenza virus subtype H5N1 escaping neutralization: more than HA variation.

Authors:  Dirk Höper; Donata Kalthoff; Bernd Hoffmann; Martin Beer
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

5.  Consequences of host heterogeneity, epitope immunodominance, and immune breadth for strain competition.

Authors:  Sarah Cobey; Mercedes Pascual
Journal:  J Theor Biol       Date:  2010-11-18       Impact factor: 2.691

6.  Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection.

Authors:  Suman R Das; Scott E Hensley; William L Ince; Christopher B Brooke; Anju Subba; Mark G Delboy; Gustav Russ; James S Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

7.  An algorithm for mapping positively selected members of quasispecies-type viruses.

Authors:  J J Stewart; P Watts; S Litwin
Journal:  BMC Bioinformatics       Date:  2001-03-06       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.